- Home
- MLTX vs ACHC Comparison
MLTX vs ACHC Comparison
Compare MLTX & ACHC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | MLTX | ACHC |
|---|---|---|
| Founded | 2021 | 2005 |
| Country | Switzerland | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Medical Specialities |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 1.1B |
| IPO Year | 2020 | 2011 |
Fundamental Metrics
Financial Performance| Metric | MLTX | ACHC |
|---|---|---|
| Price | $17.67 | $23.42 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 10 | 14 |
| Target Price | ★ $24.80 | $22.14 |
| AVG Volume (30 Days) | 1.2M | ★ 4.0M |
| Earning Date | 06-01-2026 | 05-25-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $3,312,769,000.00 |
| Revenue This Year | N/A | $4.87 |
| Revenue Next Year | N/A | $5.50 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 5.04 |
| 52 Week Low | $5.95 | $11.43 |
| 52 Week High | $62.75 | $31.43 |
Technical Indicators
Market Signals| Indicator | MLTX | ACHC |
|---|---|---|
| Relative Strength Index (RSI) | 57.13 | 85.69 |
| Support Level | $14.84 | $23.50 |
| Resistance Level | $19.15 | $25.11 |
| Average True Range (ATR) | 0.99 | 1.15 |
| MACD | 0.01 | 0.88 |
| Stochastic Oscillator | 54.74 | 98.67 |
Price Performance
Historical ComparisonAbout MLTX MoonLake Immunotherapeutics
MoonLake Immunotherapeutics is a clinical-stage biotechnology company advancing therapies to address unmet needs in inflammatory skin and joint diseases. The company is focused on the development of SLK, a novel tri-specific IL-17A and IL-17F inhibiting Nanobody that has the potential, based on response levels seen in clinical trials, to drive disease modification in dermatology and rheumatology patients.
About ACHC Acadia Healthcare Company Inc.
Acadia Healthcare Co Inc acquires and develops behavioral healthcare facilities. Acute inpatient psychiatric facilities and specialty treatment facilities contribute the vast majority of Acadia's revenue in the United States. The company's revenue is derived from services rendered to patients for inpatient psychiatric and substance abuse care, outpatient psychiatric care, and adolescent residential treatment.